PDA critical of GPhC proposals for standards for pharmacy premises

PDA critical of GPhC proposals for standards for pharmacy premises

October 23 2017 The Pharmacists’ Defence Association has warned that the pharmacy regulator...

ICO announces further resources for small businesses over GDPR compliance

ICO announces further resources for small businesses over GDPR compliance

October 23 2017 The Information Commissioner’s Office has announced it will set up a...

PDA lobbies for pharmacists to be covered by Assault on Emergency Workers (offences) Bill

PDA lobbies for pharmacists to be covered by Assault on Emergency Workers (offences) Bill

October 23 2017 The Pharmacists’ Defence Association is lobbying MPs to support the...

RPS calls for Crown indemnity for all pharmacists

RPS calls for Crown indemnity for all pharmacists

October 20 2017 The Royal Pharmaceutical Society is calling for the government to provide...

CQC annual report promotes pharmacy role to help health and social care pressures

CQC annual report promotes pharmacy role to help health and social care pressures

October 13 2017 PSNC has called on the NHS to make greater use of community pharmacy services, in...

  • PDA critical of GPhC proposals for standards for pharmacy premises

    PDA critical of GPhC proposals for standards for pharmacy premises

    Monday, 23 October 2017 09:30
  • ICO announces further resources for small businesses over GDPR compliance

    ICO announces further resources for small businesses over GDPR compliance

    Monday, 23 October 2017 09:02
  • PDA lobbies for pharmacists to be covered by Assault on Emergency Workers (offences) Bill

    PDA lobbies for pharmacists to be covered by Assault on Emergency Workers (offences) Bill

    Monday, 23 October 2017 08:58
  • RPS calls for Crown indemnity for all pharmacists

    RPS calls for Crown indemnity for all pharmacists

    Friday, 20 October 2017 09:14
  • CQC annual report promotes pharmacy role to help health and social care pressures

    CQC annual report promotes pharmacy role to help health and social care pressures

    Friday, 13 October 2017 09:51

Umesh Modi is a chartered accountant, and Pamini Jatheeskumar is a chartered certified accountant at Silver Levene...
  Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead...
Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead pharmacist, Health and Wellbeing Directorate, Public Health England
More inWhite Papers  

a lady pharmacist talking to patient cbSeptember 20 2017

The NHS is set to encourage greater uptake of biosimilar medicines in an attempt to cut overall spending on medicines.

Simon Stevens, NHS England Chief Executive, has announced a number of measures to use new technologies and innovations to transform patient care. Among his proposals are to:

  • accelerate and widen the uptake of biosimilars with estimated savings of up to £300m a year by 2021;
  • take up new oral treatments for hepatitis C which could save NHS England more than £50m and save “thousands more lives”;
  • expand the “test-bed programme testing the treatments and care models of tomorrow”.

NHS England says that more biological medicines are due to lose patent exclusivity and more biosimilar medicines are expected to come into the marketplace. “Biosimilars that are already delivering safe, effective treatment for patients and cost savings for the NHS,” include:

  • biosimilar infliximab, used to treat rheumatology conditions and inflammatory bowel disease, which came on the market in March 2015, and is currently being used by 80% of patients;
  • biosimilar etanercept, used to treat rheumatology conditions, which became available in April 2016, and 58% of patients are using it.

“Switching to these two latest biosimilars has already saved the NHS approximately £160 million per annum.”

Earlier this year, biosimilar rituximab, used in cancer and rheumatoid arthritis, became available, and biosimilar adalimumab will become available in 2018, for use in rheumatology conditions and inflammatory bowel disease. “This will offer a biosimilar alternative to the current medicine which accounts for the highest spend in hospitals – more than £300 million in 2015-16,” said NHS England.

“The introduction of lower cost biosimilar medicines has the dual advantage of also driving down the cost of the original drug. For example, the cost per defined daily dose for infliximab has fallen by nearly two-thirds from £16.80 to £6.84.”

Link:
NHS England announcement        

Legal & Policy News

October 23 2017 The Pharmacists’ Defence Association has warned that the pharmacy regulator may not be doing its utmost to protect public safety.
December 7 2015 Pharmacists in Scotland have been asked to share their views on what politicians need to be made aware of ahead of the Scottish Parliament elections in 2016. The Royal Pharmaceutical Society...